Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib Add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NCT07340138Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelabresib in myelofibrosis (MF), sponsored by Novartis. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events at 4 years. Started Apr 2026; status: active, not recruiting.
02
Drugs
pelabresib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07340138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340138.